|
DE59010908D1
(de)
|
1989-09-12 |
2000-08-10 |
Hoffmann La Roche |
TNF-bindende Proteine
|
|
US5635599A
(en)
|
1994-04-08 |
1997-06-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Fusion proteins comprising circularly permuted ligands
|
|
WO1999023114A1
(en)
|
1997-10-31 |
1999-05-14 |
Biomira Inc. |
Muc-1 derivatives and their use in treating cancer-associated muc-1 mucin-induced immunosuppression
|
|
AU2903999A
(en)
|
1998-03-12 |
1999-09-27 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
|
|
CA2324205A1
(en)
|
1998-04-03 |
1999-10-14 |
University Of Washington |
Circularly permuted biotin binding proteins
|
|
EP1151012A4
(en)
|
1998-11-19 |
2003-01-08 |
Smithkline Beecham Corp |
ANTAGONIST ANTIBODIES OF RHAMM
|
|
US6428985B1
(en)
|
1998-12-02 |
2002-08-06 |
The Regents Of The University Of Michigan |
Immunosuppressive structural definition of IL-10
|
|
ATE407697T1
(de)
|
1999-07-13 |
2008-09-15 |
Bolder Biotechnology Inc |
Erythropoietin immunglobulin fusionsproteine
|
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
|
AU2001231532A1
(en)
|
2000-02-11 |
2001-08-20 |
Maxygen Aps |
Improved interleukin 10
|
|
JP2003530384A
(ja)
|
2000-04-06 |
2003-10-14 |
メルク フロスト カナダ アンド カンパニー |
カテプシンシステインプロテアーゼ阻害薬
|
|
SI1724284T1
(sl)
|
2000-12-07 |
2009-12-31 |
Lilly Co Eli |
Glp-1 fuzijski proteini
|
|
HUP0400698A3
(en)
|
2001-02-06 |
2006-01-30 |
Merck Patent Gmbh |
Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
|
|
WO2003010201A2
(en)
|
2001-07-20 |
2003-02-06 |
Absorber, Ab |
Blood group antigen fusion polypeptides and methods of use thereof
|
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US7638323B2
(en)
|
2002-08-09 |
2009-12-29 |
Recopharma Ab |
Fusion proteins and methods of producing same
|
|
WO2004044006A1
(en)
|
2002-11-14 |
2004-05-27 |
Maxygen, Inc. |
Conjugates of interleukin-10 and polymers
|
|
WO2004060911A2
(en)
|
2002-12-30 |
2004-07-22 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
|
SI1624891T2
(sl)
|
2003-05-06 |
2013-09-30 |
Biogen Idec Hemophilia Inc. |
Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
|
|
US7696322B2
(en)
|
2003-07-28 |
2010-04-13 |
Catalent Pharma Solutions, Inc. |
Fusion antibodies
|
|
US20150071948A1
(en)
|
2003-09-26 |
2015-03-12 |
Gregory Alan Lazar |
Novel immunoglobulin variants
|
|
WO2005034863A2
(en)
|
2003-10-03 |
2005-04-21 |
Jarikuma Corporation |
Countermeasures against malaria
|
|
WO2005042573A1
(en)
|
2003-10-24 |
2005-05-12 |
Dana-Farber Cancer Institute, Inc. |
Modulation of the interaction of muc1 with muc1 ligands
|
|
US8454963B2
(en)
|
2003-11-13 |
2013-06-04 |
Musc Foundation For Research Development |
Tissue targeted complement modulators
|
|
US7576183B2
(en)
|
2003-12-24 |
2009-08-18 |
Los Alamos National Security, Llc |
Structure-based receptor MIMICS targeted against bacterial superantigen toxins
|
|
US7851463B2
(en)
|
2004-10-14 |
2010-12-14 |
Abbott Gmbh & Co. Kg |
Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
|
|
CA2588449A1
(en)
|
2004-11-24 |
2006-06-01 |
Therakine Corporation |
An implant for intraocular drug delivery
|
|
KR20080013853A
(ko)
|
2005-02-23 |
2008-02-13 |
사이케노믹스, 인코퍼레이티드 |
복수매개물질 도파민 수송체 저해물질 및 이와 관련된 용도
|
|
US7829679B2
(en)
|
2005-08-12 |
2010-11-09 |
Riken |
Mucin-type glycoprotein and use thereof
|
|
JPWO2007063907A1
(ja)
|
2005-11-30 |
2009-05-07 |
塩野義製薬株式会社 |
ペプチド糖鎖付加体およびそれを有効成分とする医薬
|
|
ATE437889T1
(de)
|
2005-12-02 |
2009-08-15 |
Apceth Gmbh & Co Kg |
Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration
|
|
WO2008140595A2
(en)
|
2006-12-01 |
2008-11-20 |
President And Fellows Of Harvard College |
Synthetic trivalent haptens, complexes thereof, and uses therefor
|
|
WO2008120093A1
(en)
*
|
2007-04-03 |
2008-10-09 |
Pfizer Inc. |
Sulfonamides and pharmaceutical compositions thereof
|
|
WO2008133928A2
(en)
|
2007-04-27 |
2008-11-06 |
The Gi Company, Inc. |
Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
|
|
CA2695374A1
(en)
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
|
WO2009076236A2
(en)
|
2007-12-06 |
2009-06-18 |
Pain Therapeutics, Inc. |
Micronized opioid compositions, formulations and dosage forms and methods of making same
|
|
US8258163B2
(en)
|
2008-06-04 |
2012-09-04 |
Board Of Regents, The University Of Texas System |
Small-molecule agonists for type-2 orexin receptor
|
|
BRPI0914889A2
(pt)
|
2008-06-17 |
2015-11-24 |
Otsuka Chemical Co Ltd |
peptídeo glp-1 adicionado de cadeia oligossacarídica
|
|
RU2518471C2
(ru)
|
2008-08-14 |
2014-06-10 |
Тиботек Фармасьютикалз |
Макроциклические индольные производные, применимые в качестве ингибиторов вируса гепатита с
|
|
JP2012525415A
(ja)
|
2009-05-01 |
2012-10-22 |
オプソテツク・コーポレイシヨン |
眼科疾患を処置または予防するための方法
|
|
AU2010264095B2
(en)
|
2009-06-26 |
2013-07-11 |
Biogen Ma Inc. |
Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
|
|
KR20120107122A
(ko)
|
2009-12-22 |
2012-09-28 |
노파르티스 아게 |
치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질
|
|
US20130089554A1
(en)
|
2009-12-29 |
2013-04-11 |
Emergent Product Development Seattle, Llc |
RON Binding Constructs and Methods of Use Thereof
|
|
AR080993A1
(es)
|
2010-04-02 |
2012-05-30 |
Hanmi Holdings Co Ltd |
Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
|
|
CN101962413B
(zh)
|
2010-09-21 |
2013-03-13 |
中国科学技术大学 |
具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用
|
|
KR101333958B1
(ko)
|
2010-10-20 |
2013-11-27 |
주식회사 한독 |
인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
|
|
EP2457579A1
(en)
|
2010-11-26 |
2012-05-30 |
Technische Universität Dresden |
Covalently linked interleukin -10
|
|
TWI622597B
(zh)
|
2011-03-28 |
2018-05-01 |
賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
|
US9527807B2
(en)
|
2011-04-05 |
2016-12-27 |
Takeda Pharmaceutical Company Limited |
Sulfonamide derivative and use thereof
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US11492383B2
(en)
|
2011-06-24 |
2022-11-08 |
Stephen D. Gillies |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
LT2748201T
(lt)
|
2011-08-23 |
2018-02-26 |
Roche Glycart Ag |
Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
|
|
EP2836485B1
(en)
|
2012-03-17 |
2018-01-10 |
Polyphor Ag |
Conformationally constrained, fully synthetic macrocyclic compounds
|
|
US9062120B2
(en)
|
2012-05-02 |
2015-06-23 |
Janssen Biotech, Inc. |
Binding proteins having tethered light chains
|
|
EP2851429B1
(en)
|
2012-05-18 |
2019-07-24 |
Adda Biotech Inc. |
Protein and protein conjugate for diabetes treatment, and applications thereof
|
|
US9156897B2
(en)
|
2012-06-08 |
2015-10-13 |
Alkermes, Inc. |
Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
|
|
CN104640561A
(zh)
|
2012-07-23 |
2015-05-20 |
酵活有限公司 |
包含轻链和重链的选择性配对的免疫球蛋白构建体
|
|
US9346872B2
(en)
|
2012-08-08 |
2016-05-24 |
Roche Glycart Ag |
Interleukin-10 fusion proteins
|
|
WO2014151910A1
(en)
|
2013-03-15 |
2014-09-25 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
JP2016526014A
(ja)
|
2013-04-24 |
2016-09-01 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
インターロイキン−１０組成物及びその使用
|
|
WO2014198880A1
(en)
|
2013-06-14 |
2014-12-18 |
Ferrer Internacional, S.A. |
2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
|
|
EP3027647A4
(en)
|
2013-07-31 |
2017-01-04 |
Amgen Inc. |
Stabilization of fc-containing polypeptides
|
|
US20160250224A1
(en)
|
2013-09-24 |
2016-09-01 |
The Board Of Regents Of The University Of Texas System |
Orexin-control of bone formation and loss
|
|
WO2015073707A1
(en)
|
2013-11-15 |
2015-05-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating heart failure with agonists of hypocretin receptor 2
|
|
SG11201604639YA
(en)
|
2013-12-12 |
2016-07-28 |
Univ Tsukuba |
Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
|
|
BR112016016658A2
(pt)
|
2014-02-06 |
2018-01-23 |
F. Hoffmann-La Roche Ag |
proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
|
|
JP6552117B2
(ja)
|
2014-03-28 |
2019-07-31 |
国立大学法人 筑波大学 |
敗血症の予防治療剤
|
|
JP6715239B2
(ja)
|
2014-09-11 |
2020-07-01 |
ヤンセン ファーマシューティカ エヌ．ベー． |
置換２−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用
|
|
CN104403004B
(zh)
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
|
EP3233920B1
(en)
|
2014-12-19 |
2020-08-26 |
Alkermes, Inc. |
Single chain fc fusion proteins
|
|
WO2016101119A1
(en)
|
2014-12-23 |
2016-06-30 |
Merck Sharp & Dohme Corp. |
Fused heteroaryl derivatives as orexin receptor antagonists
|
|
WO2016133160A1
(ja)
|
2015-02-19 |
2016-08-25 |
国立大学法人筑波大学 |
スルホンアミド誘導体またはその薬学的に許容される酸付加塩
|
|
CA2989146A1
(en)
|
2015-06-12 |
2016-12-15 |
Board Of Regents, The University Of Texas System |
Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof
|
|
DK3310784T3
(da)
|
2015-06-17 |
2020-11-09 |
Pfizer |
Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
|
|
WO2017035354A1
(en)
|
2015-08-26 |
2017-03-02 |
Blueprint Medicines Corporation |
Compounds and compositions useful for treating disorders related to ntrk
|
|
AU2016315878A1
(en)
|
2015-09-03 |
2018-03-29 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
US10377770B2
(en)
|
2015-12-18 |
2019-08-13 |
Novartis Ag |
Tricyclic compounds and compositions as kinase inhibitors
|
|
SG11201806429PA
(en)
|
2016-02-04 |
2018-08-30 |
Takeda Pharmaceuticals Co |
Substituted piperidine compound and use thereof
|
|
US11291721B2
(en)
|
2016-03-21 |
2022-04-05 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
WO2018005226A2
(en)
|
2016-06-22 |
2018-01-04 |
Alkermes, Inc. |
Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
|
|
JP6957598B2
(ja)
|
2017-03-08 |
2021-11-02 |
武田薬品工業株式会社 |
置換ピロリジン化合物およびその用途
|
|
JP7012703B2
(ja)
|
2017-03-08 |
2022-02-14 |
武田薬品工業株式会社 |
置換ピロリジン化合物およびその用途
|
|
US11319286B2
(en)
|
2017-08-03 |
2022-05-03 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and application thereof
|
|
US10428023B2
(en)
|
2017-08-03 |
2019-10-01 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
|
CN111132975B
(zh)
|
2017-09-28 |
2023-05-23 |
勃林格殷格翰国际有限公司 |
N-(2,2-二氟乙基)-n-[(嘧啶基氨基)丙基]芳基甲酰胺
|
|
JP7170996B2
(ja)
|
2017-12-12 |
2022-11-15 |
国立大学法人 筑波大学 |
スルホンアミド誘導体またはその薬学的に許容される酸付加塩
|
|
WO2019191327A1
(en)
|
2018-03-27 |
2019-10-03 |
Board Of Regents, The University Of Texas System |
Ox2r compounds
|
|
US11655241B2
(en)
|
2018-06-29 |
2023-05-23 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
|
EP3816154B1
(en)
|
2018-06-29 |
2025-04-23 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and application thereof
|
|
JP7408569B2
(ja)
|
2018-12-12 |
2024-01-05 |
武田薬品工業株式会社 |
複素環化合物
|
|
JP7379374B2
(ja)
|
2018-12-12 |
2023-11-14 |
武田薬品工業株式会社 |
複素環化合物
|
|
PE20211700A1
(es)
|
2019-01-31 |
2021-09-01 |
Takeda Pharmaceuticals Co |
Compuesto heterociclico y su uso
|
|
WO2020167701A1
(en)
|
2019-02-13 |
2020-08-20 |
Merck Sharp & Dohme Corp. |
Pyrrolidine orexin receptor agonists
|
|
US11098029B2
(en)
|
2019-02-13 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
|
EP4010314B1
(en)
|
2019-08-08 |
2024-02-28 |
Merck Sharp & Dohme LLC |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
|
JP2022547604A
(ja)
|
2019-09-13 |
2022-11-14 |
武田薬品工業株式会社 |
過度の眠気の治療のためのオレキシン２受容体アゴニストの使用
|
|
CN110642684B
(zh)
|
2019-10-15 |
2022-07-26 |
天津师范大学 |
一类基于联苯芳烃的大环和笼状分子及衍生化合物及其合成方法与应用
|
|
KR20260083444A
(ko)
|
2019-11-25 |
2026-06-05 |
알케르메스,인코포레이티드 |
치환된 마크로사이클릭 화합물 및 관련 치료 방법
|
|
WO2021106975A1
(ja)
|
2019-11-27 |
2021-06-03 |
武田薬品工業株式会社 |
複素環化合物
|
|
US11352357B2
(en)
|
2019-11-27 |
2022-06-07 |
Sumitomo Dainippon Pharma Co., Ltd. |
Cycloalkylurea derivative
|
|
CA3167050A1
(en)
|
2020-01-10 |
2021-07-15 |
Takeda Pharmaceutical Company Limited |
A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450
|
|
CN119235864A
(zh)
|
2020-07-17 |
2025-01-03 |
卫材R&D管理有限公司 |
取代的哌啶化合物及其用途
|
|
WO2022040058A1
(en)
|
2020-08-18 |
2022-02-24 |
Merck Sharp & Dohme Corp. |
Cyclopentapyrrole orexin receptor agonists
|
|
US20230365533A1
(en)
|
2020-08-18 |
2023-11-16 |
Merck Sharp & Dohme Llc |
Bicycloheptane pyrrolidine orexin receptor agonists
|
|
CN116635393A
(zh)
|
2020-09-03 |
2023-08-22 |
欧瑞夏治疗有限公司 |
中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途
|
|
US12503475B2
(en)
|
2020-09-03 |
2025-12-23 |
Centessa Pharmaceuticals (Uk) Limited |
Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
|
|
JP2022064180A
(ja)
|
2020-10-13 |
2022-04-25 |
武田薬品工業株式会社 |
複素環化合物
|
|
WO2022094012A1
(en)
|
2020-11-02 |
2022-05-05 |
Merck Sharp & Dohme Corp. |
Macrocyclic urea orexin receptor agonists
|
|
EP4247801A4
(en)
|
2020-11-23 |
2024-10-30 |
Merck Sharp & Dohme LLC |
3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS
|
|
US12552767B2
(en)
|
2020-12-03 |
2026-02-17 |
Merck Sharp & Dohme Llc |
3-heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
|
US12692262B2
(en)
|
2020-12-16 |
2026-07-28 |
Merck Sharp & Dohme Llc |
Substituted ureas as orexin receptor agonists
|
|
US11760747B2
(en)
|
2020-12-21 |
2023-09-19 |
Alkermes, Inc. |
Substituted piperidino compounds and related methods of treatment
|
|
US12006330B2
(en)
|
2020-12-21 |
2024-06-11 |
Alkermes, Inc. |
Substituted macrocyclic compounds and related methods of treatment
|
|
JP7860139B2
(ja)
|
2021-03-03 |
2026-05-15 |
リサーチ トライアングル インスティテュート |
オレキシン受容体アゴニストとしてのアリールスルホンアミド
|
|
WO2022207935A1
(en)
|
2021-04-02 |
2022-10-06 |
Orexia Therapeutics Limited |
2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
|
|
MX2023012971A
(es)
|
2021-05-03 |
2024-01-16 |
Jazz Pharmaceuticals Ireland Ltd |
Agonistas del receptor de orexina y sus usos.
|
|
JPWO2022250108A1
(cg-RX-API-DMAC10.html)
|
2021-05-26 |
2022-12-01 |
|
|
|
EP4359387A1
(en)
|
2021-06-25 |
2024-05-01 |
Jazz Pharmaceuticals Ireland Limited |
Sulfonamide orexin receptor agonists and uses thereof
|
|
WO2023017180A1
(en)
|
2021-08-13 |
2023-02-16 |
Orexia Therapeutics Limited |
Peptide derivatives and related uses as orexin agonists
|